Avalo Therapeutics, Inc.
Q3 2025 13F Holders
Symbol
AVTX
CUSIP
05338F306
Type
Equity
Class
COM NEW
Num filings
72
Total reported value, excl. options
$195 M
Compare 2025 Q3 to
2026 Q3
2026 Q2
2026 Q1
2025 Q4
2025 Q2
2025 Q1
2024 Q4
2024 Q3
2024 Q2
2024 Q1
2023 Q4
Manager
Report Date
Value ($000)
Shares
Option Type